Bioverativ Therapeutics Inc.
Quick facts
Marketed products
- Advate®
- FIX · Hematology
FIX is a recombinant coagulation Factor IX that replaces deficient or dysfunctional Factor IX to restore the intrinsic coagulation pathway in patients with hemophilia B. - rFVIIIFc · Hematology
rFVIIIFc is a recombinant Factor VIII fused to the Fc domain of human immunoglobulin G, which replaces deficient clotting Factor VIII to restore hemostasis in hemophilia A patients. - Enjaymo · Immunology
Enjaymo works by blocking the activity of the complement C1s subcomponent, a part of the immune system that can mistakenly attack red blood cells.
Phase 3 pipeline
- BIIB031 (rFVIIIFc) · Hematology
rFVIIIFc is a recombinant Factor VIII fused to the Fc domain of human immunoglobulin G, which replaces deficient clotting Factor VIII to restore hemostatic function in hemophilia A. - Factor IX (rFIXFc) · Hematology
Factor IX (rFIXFc) is a recombinant clotting factor IX fused to the Fc domain of human immunoglobulin G, which replaces deficient Factor IX to restore blood coagulation in hemophilia B patients. - Factor VIII (rFVIIIFc) · Hematology
rFVIIIFc is a recombinant Factor VIII protein fused to the Fc domain of human immunoglobulin G, which replaces deficient clotting Factor VIII to restore hemostasis in hemophilia A patients. - FVIII (PK subgroup only) · Hematology
FVIII is a recombinant coagulation factor VIII that replaces deficient or dysfunctional clotting factor to restore hemostasis in hemophilia A patients.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: